WeLeader Biomedical Co

WeLeader Biomedical Co AAQS

The The AAQS of WeLeader Biomedical Co (7713.TWO) as of Oct 16, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

WeLeader Biomedical Co has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock WeLeader Biomedical Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The WeLeader Biomedical Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2020
3.00 TWD
Jan 1, 2021
3.00 TWD
Jan 1, 2022
3.00 TWD
Jan 1, 2023
3.00 TWD
Jan 1, 2024
3.00 TWD
Jan 1, 2025
3.00 TWD
The WeLeader Biomedical Co AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd is a Taiwan-based company operating in the Health Care sector, specifically within Health Care Providers & Services. Headquartered in Kaohsiung, the company focuses on the agency and trading of in vitro diagnostic instruments and reagent-related products. It provides medical testing-related services, including distribution, after-sales, and maintenance for laboratory reagents, consumables, instruments, and equipment. Additionally, the company offers construction planning for medical testing laboratories, equipment procurement, operational coaching, and ancillary services such as human resources development and training. WeLeader Biomedical also develops digital medical examination platforms. The firm primarily serves the domestic market, with its products and services mainly sold within Taiwan. The company completed its initial public offering (IPO) on January 2, 2024, and is listed under the ticker symbol 7713.TWO with ISIN TW0007713000. Its website is https://www.weleader.com.tw/. The company operates in the health care industry, emphasizing diagnostic solutions and laboratory support services within Taiwan's medical infrastructure. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

The AAQS of WeLeader Biomedical Co is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — WeLeader Biomedical Co

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — WeLeader Biomedical Co